Meglitinides drug class for Type 2 diabetes treatment include repaglinide (Prandin) and nateglinide (Starlix) as oral diabetic medications. High fasting insulin levels and a reduction in insulin action may be present in person with Type 2 diabetes symptoms but so is absent or blunted first-phase insulin response to a meal. Most sulfonylureas (except Amaryl glimepiride) increase pancreatic beta-cell insulin secretion as well as plasma insulin concentration in people with Type 2 diabetes symptoms. But sulfonylureas oral diabetic medications fail to improve first-phase insulin release. Here comes meglitinides for Type 2 diabetes treatment. Starlix (nateglinide) and Prandin (repaglinide) as oral diabetic medications do increase first-phase insulin response, allowing to control sugar levels in blood after a meal. Both Starlix 60 mg pills and Prandin 1 mg pills are rapid-acting insulin secretagogues. When Prandin or Starlix meglitinides are taken 15 to 20 minutes before a meal, postprandial glucose excersions can be contained and minimized by this oral diabetic medications. This is important because high glucose level after a meal has been linked to cardiovascular diabetic complication.
Tag Archives: Hypoglycemia
Sulfonylureas medications for Type 2 diabetes treatment were first type two medications marketed in 1957 for type 2 diabetes treatment. The first generation sulfonylureas which are tolinase, diabinese, and orinase, can improve hyperglycemia but potential drug interactions resulting in hypoglycemia make these type 2 diabetes medications less attractive than the following second generation of sulfonylureas drugs. Glipizide and glyburide drugs were introduced in 1984, with glimepiride followed in 1996.
» Read more
Any diabetes management plan should include exercise regimen. Exercise is highly beneficial for people with diabetes mellitus. The use of an insulin pump can ensure that insulin will be delivered in right amount and dangerous hypoglycemia (low blood glucose level) after exercise be avoided.
As exercise begins, free fatty acids are released from the adipose tissue (fat tissue) as an initial source of energy for muscles. Within 10 minutes of beginning exercise, the liver accelerates the production and release of glucose, which provides our muscles with a needed source of energy. Because of this, exercise can result in initial hyperglycemia (high blood glucose level), followed by postexercise hypoglycemia. An insulin pump can be very helpful in this instance because in already hyperglycemic people with diabetes who have blood glucose level more than 240 mg/dl, exercise-induced ketosis may occur. Using an insulin pump this people can administer a small insulin bolus at the beginning of exercise.
The idea behind intensive diabetes management is to maintain tight control over blood glucose levels. It is not enough to check blood glucose levels twice a day and inject insulin twice a day same time every day. For intensive diabetes management of type 1 diabetes you will ne to check your blood glucose levels five to seven (or even more) times per day and you will need to use multiple daily injections of fast-acting or regular insulin or an insulin pump.
For people without diabetes, blood glucose levels seldom go over 140 mg/dl, even after a meal. Their bodies take care of excess glucose by producing and releasing more insulin. This is some kind of internal goal for healthy body.
Hypoglycemia occurs when blood glucose levels drop too low. Hypoglycemia is not unusual for people with type 1 diabetes or type 2 diabetes who take glucose-lowering medications, such as sulfonylurea or insulin. On average, people with type 1 diabetes have on ore two episodes of hypoglycemia each week.